Connect your AI

BBNX BBNX Debt issuance costs and discount amortization

Debt issuance costs and discount amortization at other companies

Halozyme TherapeuticsHALO

$2.25M+21.6%

Other financials

Income statement

Revenue$27.6M+56.6%

Gross profit$16.4M+83.2%

Operating income-$24.3M-30.2%

Net income-$21.9M+23.6%

EPS (diluted)-$0.49+47.3%

Balance sheet

Cash & equivalents$30.2M-28.9%

Total debt$6.9M-0.9%

Total equity$271.2M-13.5%

Total assets$304.4M-9.9%

Cash flow

Operating cash flow-$23.8M-19.3%

CapEx$1.4M+314%

Free cash flow-$25.2M-24.1%

Valuation

Market cap$708.98M-8.6%

Enterprise value$685.68M—

P/S6.4×—

Profitability

Gross margin57.2%+3.2pp

Operating margin-70.1%-6.4pp

Net margin-60.3%-17.4pp

FCF margin-55.4%-14.3pp

Returns & leverage

Return on equity-22.7%—

Debt / equity0×0.0×

Current ratio10.7×-5.2×

Where this comes from

Reported directly by BBNX in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's debt issuance costs and discount amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is BBNX's debt issuance costs and discount amortization?: BBNX (BBNX) reported debt issuance costs and discount amortization of $86K in Q1 2026.